Does starting hormone therapy cause weight gain or make me hungrier?

Starting hormone therapy is not shown, in randomized trials, to cause meaningful weight gain on its own.

A Cochrane review of 22 randomized trials found no significant difference in weight gain between women using estrogen, with or without a progestogen, and women using placebo or no treatment. In the large PEPI trial, women assigned to hormone therapy gained somewhat less weight over three years than women assigned to placebo, not more. Weight gain that shows up around the same time hormone therapy starts is usually explained by something else: the menopause transition itself is linked to an acceleration in fat gain, independent of hormone therapy use, and many women start therapy in the very years when that natural shift is already underway, so the timing overlaps. Some women do notice bloating or a feeling of fullness in the first weeks of therapy, especially with oral estrogen or certain progestogens, which is usually fluid retention rather than fat gain and often settles within a few cycles or improves with a dose or formulation change. If appetite or bloating changes are pronounced, persistent, or distressing, that is worth raising with a prescriber, since the progestogen type and dose can make a real difference, rather than assuming it is an unavoidable effect of hormone therapy itself.

What to know about this answer

Trial-level averages show no meaningful weight gain from hormone therapy, but some clinicians and patients push back that this can dismiss a real individual experience of bloating or appetite change, particularly with older progestogens that lack the fluid-neutral profile of newer ones. The trial-focused view answers that self-reported symptoms need to be separated from measured weight or fat change, and that the timing overlap with the menopause transition itself confounds the perception.

What the research shows, and which source each finding rests on

A Cochrane systematic review of 22 randomized controlled trials found no statistically significant difference in weight gain between postmenopausal women using unopposed estrogen or combined estrogen-progestogen hormone therapy and women using placebo or no treatment.

?[1]

In the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, a 3-year randomized placebo-controlled trial in 875 postmenopausal women comparing placebo, unopposed estrogen, and three estrogen-progestogen regimens, women assigned to hormone therapy had somewhat less weight gain over the study period than women assigned to placebo.

?[2]?[3]

In the longitudinal SWAN cohort, the rate of fat mass gain accelerated specifically around the final menstrual period, independent of hormone therapy use, indicating that much of the body-composition change women notice around this time reflects the menopause transition itself rather than any treatment they start.

C [4]

The Menopause Society's 2022 position statement notes that the effects and risks of hormone therapy differ by type, dose, route of administration, and whether a progestogen is used, supporting individualized counseling rather than a single blanket expectation.

A [7]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

individual bloating and appetite changes are real and shouldn't be waved away by trial averages

clinicians who see patients report fluid-retention and appetite symptoms in practice, including menopause specialists writing for a general audience such as Heather Hirsch and Mary Claire Haver

randomized trial averages can mask individual variability, and older progestogens such as medroxyprogesterone acetate lack the anti-mineralocorticoid activity that newer progestogens like drospirenone have, so some formulations plausibly cause more fluid-related bloating than others even when the average trial-level weight change is null.

?[5]?[6]

the largest randomized comparisons should set the general expectation, and reported symptoms need to be separated from actual weight or fat change

the Cochrane reviewers and the PEPI trial investigators

the largest, longest randomized comparisons that directly measured body weight found no adverse effect of hormone therapy versus placebo, and the hormone therapy arms gained slightly less weight, not more; the impression that hormone therapy causes weight gain is confounded by the fact that many women start it in the same years their body composition is already shifting for reasons unrelated to treatment.

?[1]?[2]?[3]C [4]

What would settle it: A randomized trial that compares progestogen formulations head to head for appetite and fluid-related symptoms specifically among women starting hormone therapy at menopause, using validated symptom scales and objective body-composition measurement such as bioimpedance or DXA rather than self-reported weight alone. No such head-to-head trial exists in the menopausal hormone therapy population; the strongest mechanistic evidence for progestogen differences comes from oral contraceptive studies in younger, reproductive-age women.

What is really going on here

Is the change I'm noticing actually showing up as weight on the scale, or does it feel more like bloating and puffiness that comes and goes?
Did this start right when I began hormone therapy, or has it been building for a while as part of the broader menopause transition?
Am I on an oral estrogen or a progestogen that's more associated with fluid retention, and is there a different formulation worth trying?

Questions for your doctor

Is the progestogen I'm taking one that's more associated with bloating or fluid retention, and is there an alternative formulation or route?
Could my dose or route, oral versus transdermal, be contributing to what I'm feeling?
How do we tell the difference between fluid retention that may settle on its own and a change worth investigating separately?
Should we track my weight or body composition over the next few months to see whether this is a real trend or just an early adjustment?

Questions with no answer yet

Do specific progestogens used in menopausal hormone therapy, for example medroxyprogesterone acetate versus micronized progesterone versus drospirenone, differ in how often they cause bloating or fluid-retention symptoms specifically in perimenopausal and postmenopausal women, not just in younger contraceptive users?

Partly studied

What is known: The randomized evidence that drospirenone's anti-mineralocorticoid activity reduces total body water comes from reproductive-age women using it as a contraceptive for premenstrual syndrome, not from postmenopausal hormone therapy users. Direct head-to-head symptom comparisons across progestogens in the menopausal hormone therapy population have not been established.

What would test it: A randomized trial comparing progestogen formulations in women initiating menopausal hormone therapy, using validated bloating and appetite symptom scales plus objective fluid measurement such as bioimpedance as outcomes.

Why do some women report a real, persistent increase in appetite after starting hormone therapy even though trial-level weight outcomes are null on average?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Trials measure average weight change across groups, not individual appetite trajectories, so a genuine effect in a subgroup, for example women more sensitive to a particular progestogen or route, would not necessarily show up in an average result.

What would test it: A trial or cohort capturing individual variability in appetite and hunger-related hormones, such as ghrelin and leptin, before and after starting different hormone therapy formulations, rather than only group-average body weight.

Does the timing overlap between when many women start hormone therapy and when the menopause transition's natural acceleration in fat gain happens explain most of the perception that hormone therapy caused the weight gain, or is there a real but small causal contribution from treatment itself that existing trials are underpowered to detect?

Studied and negative

What is known: The largest randomized comparisons that directly measured body weight, including a 22-trial Cochrane review and the PEPI trial, found no adverse weight effect of hormone therapy versus placebo, and slightly favored the hormone therapy arms. This is a reasonably direct answer, but these trials were not specifically designed or powered to detect a small effect confined to appetite or fluid symptoms alone.

What would test it: A trial powered specifically for appetite and fluid-retention endpoints, rather than overall body weight, in women newly starting hormone therapy at the menopause transition.

Sources

1.Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev. 2000Not rated
2.The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995Not rated
3.Stefanick ML. Estrogen, progestogens and cardiovascular risk. J Reprod Med 1999Not rated
4.Changes in body composition and weight during the menopause transition.Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight 2019 · Observational study
5.Stevenson JC. A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity. J Br Menopause Soc 2006Not rated
6.Fruzzetti F, Lazzarini V, Ricci C, et al. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception 2007Not rated
7.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022 · Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping